Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.73 |
| ▸ | MAPT | P10636 | 5/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8605379 | 0.94 | RAB9A (0.72) | RAB9AMAPTALDH1A1SMN1; SMN2HTT | |
| SCHEMBL16562210 | 0.89 | KMT2A (0.78) | RAB9AMAPTALDH1A1SMN1; SMN2HTT | |
| SCHEMBL10954317 | 0.87 | KMT2A (0.71) | RAB9AMAPTALDH1A1SMN1; SMN2HTT | |
| SCHEMBL31329284 | 0.85 | ALDH1A1 (0.69) | RAB9AMAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL6584735 | 0.85 | RAB9A (0.74) | RAB9AMAPTALDH1A1SMN1; SMN2HTT | |
| SCHEMBL16560992 | 0.85 | KMT2A (0.74) | RAB9AMAPTALDH1A1HTTKMT2A | |
| SCHEMBL15648214 | 0.85 | FPR2 (0.67) | MAPTALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL12059018 | 0.85 | MAPT (0.71) | RAB9AMAPTALDH1A1SMN1; SMN2HTT | |
| SCHEMBL17148381 | 0.85 | RAB9A (0.61) | RAB9AMAPTALDH1A1SMN1; SMN2HTT | |
| SCHEMBL6171613 | 0.84 | RAB9A (1.00) | RAB9AMAPTALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115385877-A | Dihydrofuran-2-ketone compound and preparation method thereof | 嘉兴学院 | 2022-11-25 | — | — | CN | claimed |
| CN-115385877-B | Dihydrofuran-2-one compound and preparation method thereof | 嘉兴学院 | 2024-02-23 | — | — | CN | disclosed |
| CN-115385877-A | Dihydrofuran-2-ketone compound and preparation method thereof | 嘉兴学院 | 2022-11-25 | — | — | CN | disclosed |
| CN-109796423-B | Method for synthesizing 1, 3-thiazine-4-ketone under metal-free catalysis condition | 温州大学 | 2022-11-11 | — | — | CN | disclosed |
| CN-110054597-B | Thiazolidine-4-ketone derivative synthesized under condition of no metal catalyst and preparation method thereof | 温州大学 | 2022-11-08 | — | — | CN | disclosed |
| CN-111217694-B | Method for selectively reducing carbon-carbon double bond in alpha, beta-unsaturated carbonyl compound | 五邑大学 | 2022-09-30 | — | — | CN | disclosed |
| CN-110066254-B | Preparation method of isothiazole-3-ketone compound | 温州大学 | 2021-03-19 | — | — | CN | disclosed |
| CN-111217694-A | method for selectively reducing carbon-carbon double bond in α, beta-unsaturated carbonyl compound | 五邑大学 | 2020-06-02 | — | — | CN | disclosed |
| EP-1898910-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-28 | — | — | EP | disclosed |
| US-9278905-B2 | Production method for compound comprising amino group and/or hydroxyl group | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2016-03-08 | — | — | US | disclosed |
| US-9278905-B2 | Production method for compound comprising amino group and/or hydroxyl group | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20150105559-A1 | PRODUCTION METHOD FOR COMPOUND COMPRISING AMINO GROUP AND/OR HYDROXYL GROUP | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20150105559-A1 | PRODUCTION METHOD FOR COMPOUND COMPRISING AMINO GROUP AND/OR HYDROXYL GROUP | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2015-04-16 | — | — | US | disclosed |
| EP-2821389-A1 | PRODUCTION METHOD FOR COMPOUND COMPRISING AMINO GROUP AND/OR HYDROXYL GROUP | Kyushu University, National University Corporation (JP) | 2015-01-07 | — | — | EP | disclosed |
| WO-2014011663-A1 | INHIBITORS OF BACTERIAL DIGUANYLATE CYCLASE | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20130030017-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ANDRIES KOENRAAD JOZEF LODEWIJK MARCEL (BE) | 2013-01-31 | — | — | US | disclosed |
| US-20100204270-A1 | Quinoline Derivatives as Antibacterial Agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204270-A1 | Quinoline Derivatives as Antibacterial Agents | NQO2, NDUFB7, NQO1 | RAB9A 988/4885MAPT 334/4885ALDH1A1 1171/4885 |
| US-20130030017-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | NQO2, NDUFB7, NDUFA7 | RAB9A 109/4885MAPT 379/4885ALDH1A1 1777/4885 |
| US-20150105559-A1 | PRODUCTION METHOD FOR COMPOUND COMPRISING AMINO GROUP AND/OR HYDROXYL GROUP | CA7, DAO, CA4 | RAB9A 1889/4885MAPT 3708/4885ALDH1A1 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.